184 related articles for article (PubMed ID: 33077834)
1. A cell-penetrating MARCKS mimetic selectively triggers cytolytic death in glioblastoma.
Eustace NJ; Anderson JC; Warram JM; Widden HN; Pedersen RT; Alrefai H; Patel Z; Hicks PH; Placzek WJ; Gillespie GY; Hjelmeland AB; Willey CD
Oncogene; 2020 Nov; 39(46):6961-6974. PubMed ID: 33077834
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide.
Sharifi Z; Abdulkarim B; Meehan B; Rak J; Daniel P; Schmitt J; Lauzon N; Eppert K; Duncan HM; Petrecca K; Guiot MC; Jean-Claude B; Sabri S
Clin Cancer Res; 2019 Dec; 25(24):7594-7608. PubMed ID: 31540977
[TBL] [Abstract][Full Text] [Related]
3. Myristoylated alanine-rich C-kinase substrate effector domain phosphorylation regulates the growth and radiation sensitization of glioblastoma.
Eustace NJ; Anderson JC; Langford CP; Trummell HQ; Hicks PH; Jarboe JS; Mobley JA; Hjelmeland AB; Hackney JR; Pedersen RT; Cosby K; Gillespie GY; Bonner JA; Willey CD
Int J Oncol; 2019 Jun; 54(6):2039-2053. PubMed ID: 30942445
[TBL] [Abstract][Full Text] [Related]
4. MARCKS regulates growth and radiation sensitivity and is a novel prognostic factor for glioma.
Jarboe JS; Anderson JC; Duarte CW; Mehta T; Nowsheen S; Hicks PH; Whitley AC; Rohrbach TD; McCubrey RO; Chiu S; Burleson TM; Bonner JA; Gillespie GY; Yang ES; Willey CD
Clin Cancer Res; 2012 Jun; 18(11):3030-41. PubMed ID: 22619307
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma.
McNeill RS; Canoutas DA; Stuhlmiller TJ; Dhruv HD; Irvin DM; Bash RE; Angus SP; Herring LE; Simon JM; Skinner KR; Limas JC; Chen X; Schmid RS; Siegel MB; Van Swearingen AED; Hadler MJ; Sulman EP; Sarkaria JN; Anders CK; Graves LM; Berens ME; Johnson GL; Miller CR
Neuro Oncol; 2017 Oct; 19(11):1469-1480. PubMed ID: 28379424
[TBL] [Abstract][Full Text] [Related]
6. Targeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drug.
Bi J; Khan A; Tang J; Armando AM; Wu S; Zhang W; Gimple RC; Reed A; Jing H; Koga T; Wong IT; Gu Y; Miki S; Yang H; Prager B; Curtis EJ; Wainwright DA; Furnari FB; Rich JN; Cloughesy TF; Kornblum HI; Quehenberger O; Rzhetsky A; Cravatt BF; Mischel PS
Cell Rep; 2021 Nov; 37(5):109957. PubMed ID: 34731610
[TBL] [Abstract][Full Text] [Related]
7. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
[TBL] [Abstract][Full Text] [Related]
8. Alkylaminophenol and GPR17 Agonist for Glioblastoma Therapy: A Combinational Approach for Enhanced Cell Death Activity.
Doan P; Nguyen P; Murugesan A; Candeias NR; Yli-Harja O; Kandhavelu M
Cells; 2021 Aug; 10(8):. PubMed ID: 34440745
[TBL] [Abstract][Full Text] [Related]
9. Targeting the ABC transporter ABCB5 sensitizes glioblastoma to temozolomide-induced apoptosis through a cell-cycle checkpoint regulation mechanism.
Lee CAA; Banerjee P; Wilson BJ; Wu S; Guo Q; Berg G; Karpova S; Mishra A; Lian JW; Tran J; Emmerich M; Murphy GF; Frank MH; Frank NY
J Biol Chem; 2020 May; 295(22):7774-7788. PubMed ID: 32317280
[TBL] [Abstract][Full Text] [Related]
10. Myristoylated alanine rich protein kinase C substrate is a potential cancer prognostic factor that regulates cell migration and invasion in glioblastoma.
Xiang W; Peng T; Ming Y; Li S; Wang K; Wang H; Chen L; Zhou J
Oncol Rep; 2019 Apr; 41(4):2464-2470. PubMed ID: 30816497
[TBL] [Abstract][Full Text] [Related]
11. Loss of programmed cell death 10 activates tumor cells and leads to temozolomide-resistance in glioblastoma.
Nickel AC; Wan XY; Saban DV; Weng YL; Zhang S; Keyvani K; Sure U; Zhu Y
J Neurooncol; 2019 Jan; 141(1):31-41. PubMed ID: 30392087
[TBL] [Abstract][Full Text] [Related]
12. Targeting PDGFRα-activated glioblastoma through specific inhibition of SHP-2-mediated signaling.
Sang Y; Hou Y; Cheng R; Zheng L; Alvarez AA; Hu B; Cheng SY; Zhang W; Li Y; Feng H
Neuro Oncol; 2019 Nov; 21(11):1423-1435. PubMed ID: 31232447
[TBL] [Abstract][Full Text] [Related]
13. Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo.
Signore M; Pelacchi F; di Martino S; Runci D; Biffoni M; Giannetti S; Morgante L; De Majo M; Petricoin EF; Stancato L; Larocca LM; De Maria R; Pallini R; Ricci-Vitiani L
Cell Death Dis; 2014 May; 5(5):e1223. PubMed ID: 24810059
[TBL] [Abstract][Full Text] [Related]
14. Combined acetyl-11-keto-β-boswellic acid and radiation treatment inhibited glioblastoma tumor cells.
Conti S; Vexler A; Edry-Botzer L; Kalich-Philosoph L; Corn BW; Shtraus N; Meir Y; Hagoel L; Shtabsky A; Marmor S; Earon G; Lev-Ari S
PLoS One; 2018; 13(7):e0198627. PubMed ID: 29969452
[TBL] [Abstract][Full Text] [Related]
15. Targeting the effector domain of the myristoylated alanine rich C-kinase substrate enhances lung cancer radiation sensitivity.
Rohrbach TD; Jarboe JS; Anderson JC; Trummell HQ; Hicks PH; Weaver AN; Yang ES; Oster RA; Deshane JS; Steele C; Siegal GP; Bonner JA; Willey CD
Int J Oncol; 2015 Mar; 46(3):1079-88. PubMed ID: 25524703
[TBL] [Abstract][Full Text] [Related]
16. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
[TBL] [Abstract][Full Text] [Related]
17. The ALK inhibitors, alectinib and ceritinib, induce ALK-independent and STAT3-dependent glioblastoma cell death.
Kawauchi D; Takahashi M; Satomi K; Yamamuro S; Kobayashi T; Uchida E; Honda-Kitahara M; Narita Y; Iwadate Y; Ichimura K; Tomiyama A
Cancer Sci; 2021 Jun; 112(6):2442-2453. PubMed ID: 33728771
[TBL] [Abstract][Full Text] [Related]
18. Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme.
Li Z; Zhang J; Zheng H; Li C; Xiong J; Wang W; Bao H; Jin H; Liang P
J Exp Clin Cancer Res; 2019 Aug; 38(1):380. PubMed ID: 31462285
[TBL] [Abstract][Full Text] [Related]
19. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway.
Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y
Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060
[TBL] [Abstract][Full Text] [Related]
20. Enhanced Anti-Tumor Activity in Mice with Temozolomide-Resistant Human Glioblastoma Cell Line-Derived Xenograft Using SN-38-Incorporated Polymeric Microparticle.
Yang TC; Liu SJ; Lo WL; Chen SM; Tang YL; Tseng YY
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34074038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
